Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00133354 · ClinicalTrials.gov registry record · Phase 2
Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys
A Phase 2 study, sponsored by Nemours Children's Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT00133354 is a Phase 2 study that has completed, run by Nemours Children's Clinic. The registered enrollment target is 53 participants.
The verdict
NCT00133354, a Phase 2 study, has completed, sponsored by Nemours Children's Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
The purpose of this study is to see if Arimidex, an aromatase inhibitor, can delay epiphyseal fusion and increase predicted adult height in boys who are growth hormone deficient, in puberty, and who are taking growth hormone. This is a double blind, placebo controlled 3 year trial.
Interventions
- DRUG Placebo
- DRUG Growth Hormone
- DRUG Arimidex (Anastrozole)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2001-11 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00133354
The ClinicalTrials.gov registry entry for NCT00133354 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nemours Children's Clinic, which has 108 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00133354 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00133354 about?
NCT00133354 is a clinical study titled "Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys". The purpose of this study is to see if Arimidex, an aromatase inhibitor, can delay epiphyseal fusion and increase predicted adult height in boys who are growth hormone deficient, in puberty, and who are taking growth hormone. This is a double blind, placebo controlled 3 year trial.
What is the current status of trial NCT00133354?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2001-11. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00133354?
The interventions under investigation include: Placebo (DRUG), Growth Hormone (DRUG), Arimidex (Anastrozole) (DRUG).
Who is sponsoring clinical trial NCT00133354?
This trial is sponsored by Nemours Children's Clinic, which has 108 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.